Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2005 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00080977
First received: April 7, 2004
Last updated: December 18, 2013
Last verified: June 2005

April 7, 2004
December 18, 2013
June 1998
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00080977 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2
Treatment of Patients With Metastatic Renal Cell Carcinoma Who Have Failed Low Dose Intensity Interleukin-2 With High-Dose Intravenous Recombinant Interleukin-2

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill renal cell carcinoma (kidney cancer) cells.

PURPOSE: This phase II trial is studying how well high-dose intravenous interleukin-2 works in treating patients with metastatic renal cell carcinoma that has not responded to previous low-dose intravenous or subcutaneous interleukin-2.

OBJECTIVES:

  • Determine the response rate (complete, partial, and minor) in patients with metastatic renal cell carcinoma who failed prior low-dose intravenous or subcutaneous interleukin-2 (IL-2) when treated with high-dose intravenous IL-2.
  • Determine the overall survival, disease-free survival, and time to progression in patients treated with this drug.
  • Determine the toxicity of this drug in these patients.

OUTLINE: This is a pilot study.

Patients receive high-dose interleukin-2 IV every 8 hours for 15 doses followed 7-10 days later by another 15 doses (course 1).

Patients are assesed for response 2 months after initiation of treatment. Patients with responding or stable disease receive a second course of therapy. Patients with an ongoing response receive subsequent courses of treatment in the absence of unacceptable toxicity.

Patients are followed every 6 months for survival.

PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.

Interventional
Phase 2
Primary Purpose: Treatment
Kidney Cancer
Biological: aldesleukin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
Not Provided
Not Provided
Not Provided

DISEASE CHARACTERISTICS:

  • Histologically confirmed renal cell carcinoma

    • Metastatic disease
    • No pure papillary or sarcomatoid variants
  • Measurable disease
  • Failed prior subcutaneous OR intravenous (dose ≤ 50,000 IU/kg/day) interleukin-2

    • Documented disease progression
  • No estimated hepatic replacement by tumor > 25% by CT scan or MRI
  • No tumor involving the CNS or a major nerve

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • Karnofsky 80-100%

Life expectancy

  • More than 3 months

Hematopoietic

  • Platelet count ≥ 80,000/mm^3
  • No sites of ongoing bleeding

Hepatic

  • See Disease Characteristics
  • Bilirubin ≤ 1.4 mg/dL
  • AST and ALT ≤ 3 times normal
  • PT or PTT INR ≤ 1.2
  • Hepatitis B surface antigen negative
  • Hepatitis C virus negative
  • No coagulation disorders

Renal

  • Creatinine ≤ 1.6 mg/dL

Cardiovascular

  • No ongoing ischemia*
  • No cardiac dysfunction*
  • No abnormal ejection fraction* NOTE: *A cardiac stress test is indicated for all patients ≥ 50 years of age and for any patient with possible cardiac disease as suggested by history, physical exam, or electrocardiogram

Pulmonary

  • FEV_1 ≤ 65% of predicted*
  • Vital capacity ≤ 65% of predicted* NOTE: *Pulmonary function tests are to be performed on any patient with a significant smoking history or suspected pulmonary disease either by history, physical exam, or radiograph

Other

  • HIV negative
  • No AIDS
  • No systemic infections
  • No other malignancy except carcinoma in situ
  • No psychiatric illness that would preclude study participation or compliance
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • See Disease Characteristics

Chemotherapy

  • Not specified

Endocrine therapy

  • No concurrent steroids

Radiotherapy

  • Not specified

Surgery

  • Not specified

Other

  • More than 28 days since other prior treatment for renal cell cancer
  • No concurrent immunosuppressive agents
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00080977
CDR0000357581, CMC-10-01-01AH
Not Provided
Not Provided
Blumenthal Cancer Center at Carolinas Medical Center
Not Provided
Study Chair: Richard L. White, MD Blumenthal Cancer Center at Carolinas Medical Center
National Cancer Institute (NCI)
June 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP